Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
企業コードSLGL
会社名Sol Gel Technologies Ltd
上場日Feb 01, 2018
最高経営責任者「CEO」- -
従業員数34
証券種類Ordinary Share
決算期末Feb 01
本社所在地Golda Meir 7
都市NESS-ZIONA
証券取引所NASDAQ Capital Market Consolidated
国Israel
郵便番号- -
電話番号97289313433
ウェブサイトhttp://www.sol-gel.com
企業コードSLGL
上場日Feb 01, 2018
最高経営責任者「CEO」- -
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし